Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
British Journal of Cancer|June 15, 2006
Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literatureG Des Guetz, B Uzzan, P Nicolas, et al.
Medical Oncology (Northwood, London, England)|April 1, 2003
Long-term survival of patients given hormonal therapy for metastatic endometrial stromal sarcomaJ-P Spano, J-C Soria, M Kambouchner, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|February 28, 2009
[Description of erlotinib-related skin effects management in France. Results of the PRECEDE study]N Janus, V Launay-Vacher, C Robert, et al.
Drugs Under Experimental and Clinical Research|January 1, 1985
Preoperative chemotherapy in epidermoid bronchogenic carcinomaJ F Morere, L Israel, J L Breau, et al.
Anticancer Research|November 2, 2010
Prognostic impact of microsatellite instability in colorectal cancer patients treated with adjuvant FOLFOXG Des Guetz, C Lecaille, P Mariani, et al.
Cancer Biomarkers : Section a of Disease Markers|May 27, 2008
Identification of a functional EGF-R/p60c-src/STAT3 pathway in colorectal carcinoma: analysis of its long-term prognostic valueA Tadlaoui Hbibi, C Lagorce, P Wind, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 2, 2010
Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphomaD Machover, B Delmas-Marsalet, S C Misra, et al.
Anticancer Research|August 19, 2007
Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancerG des Guetz, P Mariani, J Cucherousset, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 16, 2004
Impact of EGFR expression on colorectal cancer patient prognosis and survivalJ-P Spano, C Lagorce, D Atlan, et al.
Medical Oncology (Northwood, London, England)|November 6, 2010
Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysisM Bouchahda, T Macarulla, G Liedo, et al.
Pageof 4